Surgery Partners (SGRY) Stock May Be 13% Overvalued After Its Rally

Surgery Partners has seen its share price move sharply in recent weeks, which puts fresh attention on whether the current valuation lines up with the cash it can generate over time. With the spotlight back on the stock, investors are asking how its cash flows stack up against the price now attached to the business.

• The share price is up 90.4% over the past month, which raises the question of whether the recent surge is fully supported by the cash the company is expected to produce.
• The business model relies heavily on converting procedure volumes into steady operating cash, so the durability and quality of that cash generation can shape how much investors are willing to pay today.
• If you'd rather focus on sales, this one's for you. See what Surgery Partners's 1.0x P/S says about the price.

The issue now is whether the current US$26.45 share price is justified by Surgery Partners' cash flows when set against its intrinsic value estimate from the Discounted Cash Flow (DCF) model.

If you want more than a single stock story and prefer a list filtered around valuation, use a focused screen built around 33 high quality undervalued stocks as another research starting point.

Does Surgery Partners Look Pricey on Cash Flow?

The Discounted Cash Flow (DCF) approach here focuses on the cash Surgery Partners can produce for shareholders over time and then discounts that back to today. Latest twelve month free cash flow sits at about $170.9 million, with the model assuming this moves to $250 million by 2025 before easing into relatively gentle long term growth.

Those inputs describe a business expected to keep generating positive free cash rather than one built on very aggressive expansion forecasts. On that cash profile, the DCF output comes in modestly below the current $26.45 share price. This suggests the recent jump has already priced in a fair amount of the projected improvement in cash generation. Find out what Surgery Partners could be worth using our Discounted Cash Flow (DCF) estimate.

The Surgery Partners Narrative: What Would Justify Today's Price?

Narratives on Surgery Partners pick up where the valuation puzzle leaves off and explain which paths for growth, profitability and earnings would need to occur for the stock to end up worth materially more or materially less than today’s price. Each scenario connects its figures to a clear view on how Surgery Partners' growth, margins and key risks could change over time, providing a concrete reference point to revisit as new information emerges.

One of the top narratives on Surgery Partners: 25% overvalued

This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.

"The move to neutral stances indicates that, in the near term, the stock is viewed more as a merger arbitrage situation than a growth driven investment..."

Discover why this Narrative puts Surgery Partners at 25% overvalued.

Surgery Partners investors still need to weigh what could go wrong

Price and cash flow only tell part of the story for Surgery Partners, because recent research has also highlighted specific concerns that investors may want to examine before relying on any valuation alone. Take a closer look at 2 warning signs (1 major) before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com